Navigation Links
Prime Therapeutics Launches CareCentered Contracting™ Program

ST. PAUL, Minn., Sept. 22, 2011 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), today announced a new contracting program called CareCentered Contracting™, aimed at ensuring Prime members are taking effective prescription medications that truly improve their health.

Through CareCentered Contracting, pharmaceutical companies agree to either refund the cost of the drug for patients whose medication does not work as expected, such as an osteoporosis patient who suffers a fracture, or cover the cost of treating such an event. The health outcomes and medication adherence of patients are not typically factors in pricing negotiations. CareCentered Contracting includes these components in order to reduce uncertainty about the effectiveness of medications and possible side effects for members and increase accountability between pharmaceutical manufacturers and health plans.

"The health care system is increasingly focused on demonstrating greater value for the care provided," said Peter Wickersham, senior vice president of cost of care at Prime. "The same is true for pharmaceuticals. Not only do we want to make sure the drugs our members are taking are actually doing what they are supposed to do, we also want to increase the value of these drugs to health plans and members. That's why our CareCentered contracts go beyond just outcomes, to include the cost of care, medication adherence, patient education and other factors critical to improved health."

Traditionally, pharmaceutical contracts negotiated by PBMs were based solely on the volume of drugs purchased. As growing numbers of high-cost specialty products enter the market, drug manufacturers are being asked to substantiate the value their medications can provide when taken appropriately, such as keeping patients out of the hospital and slowing disease progression. As an integrated PBM, Prime is uniquely able to measure these health outcomes by coordinating pharmacy and medical data for its health plan owners.

The first two drugs with outcomes-based contracts were osteoporosis drug Actonel® from Warner Chilcott Company and diabetes drug Januvia® from Merck. With the launch of CareCentered Contracting, Prime is negotiating additional contracts in areas where rebate contracting does not currently apply.

"Outcomes-based contracts changed the game by focusing on patient outcomes, not just volume of drugs in determining costs," said Sue Scheid, Prime's vice president of trade relations. "With CareCentered Contracting we are again changing the dynamic by establishing contracts in categories like Multiple Sclerosis, and other specialty disease states. We are in discussions with several manufacturers and anticipate additional contracts to be added to the program in the near term.”

Prime Therapeutics is a pharmacy benefit management company dedicated to providing innovative, clinically-based, cost-effective pharmacy solutions for clients and members. Providing pharmacy benefit services nationwide to nearly 17 million covered lives, its client base includes Blue Cross and Blue Shield Plans, employer and union groups, and third-party administrators. Headquartered in St. Paul, Minn., Prime Therapeutics is collectively owned by 12 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those Plans. Learn more at

SOURCE Prime Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wasatch Pediatrics Selects Phreesia and Greenway PrimeSUITE to Streamline its Workflow and Increase Cash Flow
2. Greenways Remote Clinic PrimeMOBILE Available on Apples iPad
3. Prime Therapeutics Drug Trend Insights Reports One of the Lowest Drug Spending Increases in the Industry
4. PrimeraDx Launches the Only System Capable of Simultaneous Quantification of mRNA, microRNA and DNA
5. Prime Therapeutics Announces Pharmacy Offering with Guaranteed Net Spend Per Prescription
6. Michael Showalter Joins Prime Therapeutics As Chief Marketing Officer
7. Prime Therapeutics Vice President of Specialty Pharmacy Solutions Presents at 6th Annual Executive Forum on Pharmacy Benefit Management Strategies
8. Cardinal Health, Prime Therapeutics Renew Primary Distribution Agreement
9. BGI Releases a Complete De Novo E. Coli O104 Genome Assembly and is Making Its Detection Kit Protocols and Synthesized Primers Freely Available to Worldwide Disease Control and Research Agencies
10. TriLink BioTechnologies, Inc. Awarded European Patent for CleanAmp™ Primers
11. Prime Therapeutics President and CEO Eric Elliott Delivers Speech at University of Minnesota College of Pharmacy Dialogues in Managed Care Leadership 2011
Post Your Comments:
(Date:11/30/2015)... BASEL, Switzerland , Dec. 1, 2015 ... through its wholly-owned UK subsidiary Proximagen Ltd., today announced ... novel, oral small molecule inhibitor of Vascular Adhesion Protein ... in the treatment of inflammatory disease. The VAP-1 inhibitor ... --> --> Under the terms ...
(Date:11/30/2015)... , 1 décembre 2015 ... exposition et conférence d,Asie portant sur ... sur l,industrie manufacturière, se tiendra à ... 20 au 22 avril 2016. ... Photo - ...
(Date:11/30/2015)... PUNE, India , December 1, 2015 ... --> adds "Endometriosis - ... that provides an overview on therapeutic pipeline ... capabilities to create effective counter strategies to ... by identifying new targets and MOAs to ...
Breaking Medicine Technology:
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... ... limb amputations in the United States. Podiatrists are well aware that psychology-based patient ... therapeutic behaviors) are often catastrophic contributors to diseases of the diabetic foot. ...
(Date:12/1/2015)... ... December 01, 2015 , ... Visage accelerates mobile ... wholly owned subsidiary of Pro Medicus Ltd. (ASX: PME), has announced they are ... of North America (RSNA) 2015 annual meeting through December 3 in Chicago, Illinois, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator of aesthetic and medical ... the devices for sale in the United States. Clarity is a Superior Dual ... Nd:YAG lasers, into a single platform that is easy to own and operate. ...
(Date:12/1/2015)... Atlanta, GA (PRWEB) , ... December 01, 2015 ... ... manufacturing, supports SACC-GA and SACC-USA through membership and leadership since 2008. ... and Chair for SACC-USA . Gary has spent a significant amount of ...
(Date:12/1/2015)... Charlotte, NC (PRWEB) , ... December 01, 2015 ... ... NHS Foundation Trust on receiving the 2015 HSJ Acute Sector Innovation Award on ... of improving the patient care experience, and propose exciting enhancements to the medical ...
Breaking Medicine News(10 mins):